- Research article
- Open Access
Safety evaluation of the antimicrobial peptide bovicin HC5 orally administered to a murine model
© Paiva et al.; licensee BioMed Central Ltd. 2013
- Received: 3 August 2012
- Accepted: 21 February 2013
- Published: 27 March 2013
Bovicin HC5 is an antimicrobial peptide that shows a broad spectrum of activity and potential for biotechnological and therapeutic applications. To gain insight about the safety of bovicin HC5 application, the histological and immunostimulatory effects of orally administrated bovicin HC5 to BALB/c mice were evaluated. BALB/c mice were divided into three groups: negative control (NC group); mice given purified bovicin HC5 (Bov group); mice given ovalbumin (positive control, PC group; a murine model of enteropathy). The mice were initially pre-sensitized, and PBS, bovicin HC5 or ovalbumin were administered for 30 days by daily gavages. Histological and morphometric analysis were performed and the relative expression of cytokines was analyzed by real-time RT-PCR.
The oral administration of bovicin HC5 to BALB/c mice reduced weight gain and caused alterations in the small intestine, although absorptive changes have not been detected. The number of total goblet cells and the mucopolysaccharides production were not affected by bovicin HC5 administration. A hypertrophy of Paneth cells and an increase in the number of mitotic cells were observed in Bov group, while the number of mast cells remained unaltered. Increased expression of TNF-α, INF-γ and IL-12 was observed in the small intestine upon bovicin HC5 administration.
Bovicin HC5 has only minor effects on intestinal permeability and did not elicit an allergenic response upon oral administration to animal models. Considering the low in vivo toxicity of bovicin HC5, it might be a good candidate for enteral applications.
- Streptococcus bovis HC5
- BALB/c mice
Bacteriocins are antimicrobial peptides produced by many species of bacteria and some members of the Archaea domain. Nisin, the most well-known bacteriocin, is produced by Lactococcus lactis strains and it belongs to the lantibiotic class of bacteriocins; nisin has GRAS status (Generally Recognized as Safe) and is currently the only bacteriocin approved for use as a food preservative . Other bacteriocins, such as pediocin PA-1/AcH and lacticin 3147, are also commercially available, but are marketed as fermentates of lactic acid bacteria (LAB) having GRAS status .
The targeted mechanism of action and the relatively low propensity to select resistant bacteria are attractive properties of the lantibiotics. Moreover, previous studies have demonstrated the efficacy of many lantibiotics against target bacteria  and also the potential for biotechnological and therapeutic applications of these peptides . Despite the good results obtained in vitro, the large scale application of lantibiotics remains limited due to the lack of data regarding clinical aspects, including the destiny of the peptides after ingestion, the loss of antimicrobial activity, the cytotoxicity and the immunostimulatory effects triggered by these peptides in vivo .
In order to evaluate the in vivo toxicity, an antimicrobial peptide should be administered daily and repeatedly to an animal model for a required period of time [6, 7], and the route of administration should be the same proposed for use in vivo . Because lantibiotics generally have low molecular mass and little intrinsic immunogenicity, coupling of these peptides to protein carriers or the use of adjuvants can be useful strategies to enhance the immunogenicity [9, 10].
Bovicin HC5, a lantibiotic produced by the ruminal bacterium Streptococcus bovis HC5, has desirable properties, such as broad spectrum of activity, stability to low pH and high temperatures [11, 12]. The mechanism of action of bovicin HC5 was recently elucidated and it is based on the specific interaction with lipid II molecule, leading to inhibition of the bacterial cell wall synthesis and eventually to pore-formation . Previous results indicated that the in vitro toxicity of bovicin HC5 against mammalian cells is comparable to nisin . Bovicin HC5 has been suggested as a potential alternative to classical antibiotics in livestock production and as an additive for food preservation [15, 16].
To gain insight about the safety use of bovicin HC5 on animal hosts, we analyzed the effects of orally administrated bovicin HC5 to BALB/c mice, focusing on gastrointestinal permeability, morphological alterations in the GI tract and the immunostimulatory effects of the peptide. We used a murine model of enteropathy induced by sensitization to compare the effects caused by the administration of bovicin HC5.
The administration of bovicin HC5 induces less weight gain in BALB/c mice
The weight of BALB/c mice was monitored during the trial period to verify if the sensitization followed by challenge with bovicin HC5 or ovalbumin affected weight gain of the animals, which could indicate clinical manifestation of allergy or gastrointestinal disorders. Symptoms as diarrhea, intestinal bleeding or rectal prolapsed were not observed.
Prior to the experiment, no significant differences were detected among the average weight of the mice (18.5, 18.4 and 18.3 g to NC, Bov and PC groups, respectively). In the NC group, the average mice weight ranged from 18.5 ± 0.35 g (day 0) to 20.8 ± 0.31 g (day 58), or a weight gain of 11.01% along the trial period.
Gastrointestinal permeability is not altered upon oral administration of bovicin HC5
Oral administration of bovicin HC5 and ovalbumin induce histological and morphometric alterations in the intestine of BALB/c mice
Morphometric analysis of the small and large intestine of the animals treated with bovicin HC5 or ovalbumin showed some impairment of the intestinal structure integrity, but the severity of the alterations caused by bovicin HC5 and ovalbumin was clearly different.
In PC group, the jejunum segments demonstrated a significant increase (p < 0.05) in the number of mast cells from the mucosa and submucosa (Figure 7), when compared to Bov and NC groups.
Assessment of the immunostimulatory effects on spleen and small intestine of animals treated with bovicin HC5 or ovalbumin
In this study, we used a murine model of food-induced enteropathy in order to compare the morphological and immunostimulatory effects of the orally administered bovicin HC5. In our positive control group, the breakdown of mucosal tolerance was obtained by oral administration of the non-tolerogenic antigen ovalbumin (OVA). OVA has become a reference protein for immunological and biochemical studies, being widely used as an antigen for studying allergic diseases in mice .
The model used to induce food enteropathy worked properly, and an inflammatory reaction was developed in the small intestine. OVA administration altered the small intestinal architecture, increased protein permeability, caused edema and decrease the mucosal thickness in the large intestine. In contrast, upon oral administration of bovicin HC5, only minor histological alterations indicative of inflammation or alterations on permeability were observed, although an atrophy of the villi and destruction of the apical portion of the villi were detected in some regions of the small intestine.
The degree of impairment of the small intestine could explain the differences observed in weight gain between Bov and PC groups throughout the experiment, since these alterations may have influenced the absorption of nutrients. Saldanha et al. reported that BALB/c mice previously sensitized lost weight after challenging with OVA, which remained until the end of the experiment.
In normal conditions, the number of mast cells in the intestine is relatively constant, but hyperplasia can be observed during inflammatory reactions or during stages of remodeling/repair of inflammatory disorders . As a result of the food enteropathy developed upon administration of OVA, we observed increased number of mast cells in the small intestine of PC group. However, no alterations were observed in the mast cell population from the Bov group.
Bacterial products or cell components may induce metaplasia, proliferation and hypersecretion of goblet cells . In this study, animals treated with OVA showed reduced number of goblet cells in the small intestine, and a reduction in the secretion of acidic and neutral mucins. In contrast, the administration of bovicin HC5 did not alter the total number or the pattern of goblet cell secretion. The mucus protects the intestinal wall by limiting the absorption of antigens, and therefore, the hypersecretion of mucopolysaccharides was expected at the PC group, as a characteristic of allergic inflammation and as a result of increased IL-13 expression ; therefore, the reduction in the number of cells responsible for mucus secretion observed in PC group may not be related to the reduction in the secretion process per se, but to the limited count fields resulting from the destruction of the villi observed in PC group.
Similar to goblet cells, Paneth cells also play an important role in host intestinal defense mechanisms, contributing to the maintenance of the gastrointestinal barrier by secreting antimicrobial peptides and other compounds in response to bacteria and bacterial antigens [22, 23]. The presence of antigens in the gastrointestinal tract also influence the expression and activity of key proteins involved in the regulation of cell proliferation . Hypertrophy of Paneth cells and increased mitotic activity were observed in Bov and PC groups, indicating that despite the loss of villi architecture, secretion of antimicrobial compounds and tissue repair systems remained active, probably as a response to the injuries caused by bovicin HC5 and OVA in the small intestine.
Our results indicate that the effects of bovicin HC5 and ovalbumin administration are more pronounced in the intestine, which can explain the significant reduction in spleen cellularity observed in Bov and PC groups: immune cells probably migrated from the spleen to the intestine, where the main effects were observed.
OVA administration modulated the gut mucosal immunity in BALB/c mice towards significant TH2-polarized response, increasing the relative expression of IL-4, IL-5 and IL-13 mRNA. Goya et al. also observed increased mRNA levels of the TH2 cytokines IL-4, IL-5 and IL-13, as well as a decrease of INF-γ expression in the lungs of OVA-treated mice. A down modulation of regulatory mechanisms, with reduction of TGF-β and IL-10 expression, may be involved in the development of food allergy , but this pattern of cytokine expression, although expected, was not observed in this study.
The modulation of the host immune system induced by bacteriocins is a phenomenon much less understood when compared to other peptides or proteins, such as proteins extracted from mushrooms (such as LZ-8 (13 kDa) , Fip-vvo (15 kDa)  and FIP-fve (114 aa) ) and host-defense peptides [30, 31].
In contrast to the TH2-polarized response elicited by OVA, higher mRNA expression for the TH1 cytokines TNF-α, IL-12 and INF-γ were observed in the intestine of bovicin HC5-fed mice. Liu et al.  also demonstrated significant induction of IFN-γ after administration of the yam tuber storage protein dioscorin. Human cathelicidin LL-37 modulated the activity of IFN-γ on a variety of cell types , and pre-treatment with LL-37 induced IFN-γ production by monocytes, enhancing monocyte-derived dendritic cell functions, such as IL-12 secretion and TH1-polarized co-stimulatory activity .
In the present work, for the first time, the effects of the oral administration of bovicin HC5 to an animal model were described. The bovicin HC5 concentration administrated to the animals (micromolar range) was greater than the quantities required for in vitro antimicrobial activity (nanomolar range). We have previously demonstrated that bovicin HC5, in higher con-centrations, was able to permeabilize membranes in an unspecific way , but one should bear in mind that antimicrobial peptides can also modulate the microbial community composition in the intestine which could explain the partial destruction of small intestine cells caused by bovicin HC5 administration. Nonetheless, the impairment of the intestinal cells induced by bovicin HC5 neither altered the gut permeability nor was typical of an enteropathy process. Regarding the immunostimulatory effects, the results confirmed that bovicin HC5 was able to stimulate the immune system of BALB/c mice at local level (gut immune system), by influencing the cytokine release towards TH1-polarized response.
Proper pharmacokinetic studies will be needed to determine if bovicin HC5 can resist passage through the adverse conditions in the GI tract (low pH, presence of peptidolytic and proteolytic enzymes), but it should be noted that animals treated with bovicin HC5 showed more pronounced effects in the intestine compared to the animals in the negative control groups. These results suggest that the oral administration of bovicin HC5 might be a promising strategy to control microbial infections, manipulate microbial community composition or modulate immunological responses in the GI tract of the host animal.
Streptococcus bovisHC5 and bovicin HC5
Streptococcus bovis HC5 growth and bovicin HC5 extraction were performed as previously described . Purification of bovicin HC5 was performed by reversed phase-HPLC  and the purity of bovicin HC5 was confirmed by electrospray mass spectrometry to be always greater than 95%.
Bovicin HC5 stock solutions (1 mg ml-1 in PBS (10 mM, pH 7.2)) were stored at −20°C until use. Protein concentration was determined using a bicinchoninic acid protein assay (Pierce Chemical Corp., Bonn, Germany), with bovine serum albumin as the standard.
The BALB/c mice used in this study were housed in an animal facility at the Universidade Federal de Viçosa, according to standards and guidelines as set forth in the Animal Welfare Legislation, the Guide for the Care and Use of Laboratory Animals, the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) and the National Council for Animal Experimentation Control (CONCEA), following approval by the Institutional Animal Care and Use Committee (IACUC) of the Universidade Federal de Viçosa under the protocol number CEUA/UFV 97/2011.
Five-week-old female BALB/c mice were randomly divided into three experimental groups: Group 1, untreated mice (negative control, NC group); Group 2, mice given purified bovicin HC5 (Bov group); Group 3, mice given ovalbumin (Sigma Chemicals Co., St. Louis, MO, 99% of purity) (positive control, PC group). Two independent experiments were performed and a total number of eight animals were used per experimental group.
The sensitization procedure was developed based on previously established protocols . Mice from the Bov group were subcutaneously sensitized with bovicin HC5 (4 μg/g animal weight/day or approximately 70 μg/animal ), while animals from the PC group were sensitized with ovalbumin (100 μl of a 1 mg ml-1 stock solution in sterile ultrapure water, or 100 μg OVA/animal). Aluminum hydroxide was used as adjuvant (50 μl; 20 mg ml-1 stock solution in sterile saline) at the first sensitization (day 0). After three weeks, each mouse group was subcutaneously boosted (without the use of adjuvant) with the respective substances (second sensitization, day 21). The NC group was sensitized with sterile PBS (10 mM, pH 7.2), using the same procedure described above.
PBS, bovicin HC5 or ovalbumin (100 μl) were administered without adjuvant to the NC, Bov and PC groups, respectively, by daily gavages (18-gauge stainless steel feeding needles). Oral administration started one week after the second sensitization (day 28) and continued for 30 days uninterruptedly (day 58). The mice were weekly weighted and behavior, general appearance and adverse reactions were monitored daily.
The gut permeability was determined by the uptake of β-lactoglobulin (β-LG) following challenge (, with modifications]). At the end of the trial period (day 58), the animals of the NC, Bov and PC groups, were orally challenged with 200 μl of the respective samples (PBS, bovicin HC5 or ovalbumin). After thirty minutes, the animals received an oral dose of β-LG (200 μl; 100 mg ml-1 solution in distilled water) (Sigma Chemicals Co., St. Louis, MO, 90% of purity).
Blood samples were collected from the orbital plexus under light isoflurane anesthesia, after 0.5, 1, 2 and 5 h of the β-LG administration. The samples were kept at room temperature for 2 hours, and the sera were centrifuged (Eppendorf®, Centrifuge 5415C, Hamburg, Germany) at 12,000 × g, 5 min, room temperature. Sera were used for the quantification of β-LG by FPLC, using a cationic change column (Mono Q HR 5/5). The column was equilibrated with buffer A (20 mM Tris) and the β-LG was eluted with a linear gradient of 25 to 50% buffer B (20 mM Tris, 1 M NaCl), 22°C, and flow rate of 1 ml min-1. Absorbance was monitored at 220 and 280 nm.
The concentration of β-LG in animal sera was determined using a calibration curve with known concentrations of β-LG (0; 6.25; 12.5; 25.0; 50.0 mg ml-1) mixed to pre-immune serum of the animals from each group. The pre-immune serum corresponded to the sera collected prior to the initial sensitization procedure. Serum samples before β-LG administration were used as negative control. All analyses were performed in duplicate.
Histological and morphometric analysis
On day 58 the heart, liver, spleen and gut of the all the mice were aseptically collected, washed in PBS buffer (10 mM, pH 7.2), fixed in Carson formalin solution , dehydrated and embedded in resin (Historesin®, Leica). Transverse and longitudinal, 3 μm thick tissue sections were obtained and stained with hematoxylin and eosin (H&E), toluidine blue/sodium borate (1%) or with Alcian Blue (pH 2.5) combined with periodic acid-Schiff (PAS) , depending on the histological analysis that would be performed.
Ten fields of longitudinal sections stained with H&E were randomly selected and visualized with a 10× objective lens in order to perform the morphological analysis of the organs selected (villi height and width were determined from an area of 17 mm2 per animal; for mucosal thickness, an average of twenty measurements were obtained from each animal). The spleen cells were counted using ten fields of longitudinal sections visualized with a 40× objective lens, in an area of 0.23 mm2 per animal. For quantitative and qualitative analysis of goblet cells, ten fields of longitudinal sections (area of 1 mm2) stained with Alcian Blue-PAS were randomly selected and visualized with a 20× objective lens; the mucins produced by goblet cells were identified by differential staining (acid mucins in blue, neutral mucins in red, and mixed acid and neutral mucins in purple). The mast cells were counted using ten longitudinal sections stained with toluidine blue/sodium borate (1%) and visualized with a 40× objective lens; an area equivalent to 20 jejunum villi (mucosa and submucosa) was evaluated for each animal.
Digital images were captured with a light microscope (Olympus AX 60), coupled to a digital camera (Q-Color 3, Olympus). The morphometric analyzes were performed with the image analysis program Image Pro Plus 4.0 for Windows (Media Cybernetics). The results were shown as mean values ± standard error of the mean.
Analysis of relative gene expression by real-time PCR
The whole spleen and jejunum segments (100 mg of tissue) were aseptically removed, washed in sterile PBS (10 mM, pH 7.2), and individually manipulated. Cells obtained from the spleen were washed with saline (0.85%), centrifuged at 7,500 × g for 5 min (Eppendorf®, Centrifuge 5415C, Hamburg, Germany), at room temperature, and the erythrocytes were lysed using a hemolytic solution (155 mM NH4Cl, 10 mM KHCO3, pH 7.2). The splenocytes were centrifuged again and the supernatant was discarded. A jejunum segment of 6 cm was removed and washed three times with saline (0.85%), for removal of waste.
Sequences of sense (S) and antisense (AS) primers used for real time-RT-PCR analysis (18)
5′ AGC TGC GTT TTA CAC CCT TT 3′
5′ AAG CCA TGC CAA TGT TGT CT 3′
5′ TGG ACA ACA TAC TGC TAA CC 3′
5′ GGA TCA TTT CCG ATA AGG CT 3′
5′ CTG ACG GCA CAG AGC TAT TGA 3′
5′ TAT GCG AAG CAC CTT GGA AGC 3′
5′ GAG GTT ACA GAC ATG CAC CAT T 3′
5′ TCA GTT GGT AAC ATG CAC AAA G 3′
5′ ACC AAC ATC TCC AAT TGC AA 3′
5′ ATG CAA TAT CCT CTG GGT CC 3′
5′ TGT GCT CAG AGC TTT CAA CAA 3′
5′ CTT GAT GGT GGT GCA TGA GA 3′
IL-12 p40 S
5′ AGC ACC AGC TTC TTC ATC AGG 3′
IL-12 p40 AS
5′ GCG CTG GAT TCG AAC AAA G 3′
5′ GCA TCT TGG CTT TGC AGC T 3′
5′ CCT TTT TCG CCT TGC TGT TG 3′
5′ GCT GAA CCA AGG AGA CGG AAT 3′
5′ GCT GAT CCC GTT GAT TTC CA 3′
5′ GCT CCA GAA GGC CCT CAG A 3′
5′ CTT TCC CTC CGC ATT GAC A 3′
The results were demonstrated as relative level of gene expression in the experimental group, by reference to the β-actin gene in each sample, using the cycle threshold (Ct) method. Measurements were conducted in duplicates and the fold increase expression was calculated by using the expression 2^DCt, according to the instructions from Applied Biosystems User’s Bulletin #2 (P/N 4303859). Results were shown as mean values ± standard deviation.
The means of the groups were evaluated by analysis of variance (ANOVA) followed by the Dunn’s or Bonferroni’s post test. A probability value of less than 0.05 was considered statistically significant, and all the comparisons were performed using the GraphPad Prism 5.00 software (GraphPad Software, San Diego California, USA).
A.D.P. was supported by a fellowship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Grant Number AUXPE/PNPD 2439/2011, Brasília, Brazil). This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (Grant Number 201179/2009-1) and by a Grant from the Fundação de Amparo à Pesquisa de Minas Gerais (Belo Horizonte, Brazil).
- Delves-Broughton J: Nisin as a food preservative. Food Aust. 2005, 57: 525-527.Google Scholar
- Gálvez A, López RL, Abriouel H, Valdivia E, Ben ON: Application of bacteriocins in the control of foodborne pathogenic and spoilage bacteria. Crit Rev Biotechnol. 2008, 28: 125-152. 10.1080/07388550802107202.PubMedView ArticleGoogle Scholar
- Gänzle MG, Weber S, Hammes WP: Effect of ecological factors on the inhibitory spectrum and activity of bacteriocins. Int J Food Microbiol. 1999, 46: 207-217. 10.1016/S0168-1605(98)00205-0.PubMedView ArticleGoogle Scholar
- Toke O: Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers. 2005, 580: 717-735.View ArticleGoogle Scholar
- Belguesmia Y, Madi A, Sperandio D, Merieau A, Feuilloley M, Prévost H, Drider D, Connil N: Growing insights into the safety of bacteriocins: the case of enterocin S37. Res Microbiol. 2011, 162: 159-163. 10.1016/j.resmic.2010.09.019.PubMedView ArticleGoogle Scholar
- Pariza MW, Foster EM: Determining the safety of enzyme used in food processing. J Food Protect. 1983, 46: 453-468.Google Scholar
- Pariza MW, Cook M: Determining the safety of enzymes used in animal feed. Regul Toxicol Pharmacol. 2010, 56: 332-342. 10.1016/j.yrtph.2009.10.005.PubMedView ArticleGoogle Scholar
- FDA. U.S. Food and Drug Administration: Toxicological principles for the safety assessment of direct food additives and color additives used in food. 1993, Washington, D.C: U.S. FDAGoogle Scholar
- Bhunia AK: Monoclonal antibody-based enzyme immunoassay for pediocins of Pediococcus acidilactici. Appl Environ Microbiol. 1994, 60: 2692-2696.PubMedPubMed CentralGoogle Scholar
- Bhunia AK, Johnson MG, Ray B, Elden EL: Antigenic property of pediocin AcH produced by Pediococcus acidilactici H. J Appl Bacteriol. 1990, 69: 211-215. 10.1111/j.1365-2672.1990.tb01511.x.PubMedView ArticleGoogle Scholar
- Mantovani HC, Hu H, Worobo RW, Russell JB: Bovicin HC5, a bacteriocin from Streptococcus bovis HC5. Microbiology. 2002, 148: 3347-3352.PubMedView ArticleGoogle Scholar
- Houlihan AJ, Russell JB: Factors affecting the activity of bovicin HC5, a bacteriocin from Streptococcus bovis HC5: release, stability and binding to target bacteria. J Appl Microbiol. 2006, 100: 168-174. 10.1111/j.1365-2672.2005.02745.x.PubMedView ArticleGoogle Scholar
- Paiva AD, Breukink E, Mantovani HC: Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5. Antimicrob Agents Chemother. 2011, 55: 5284-5293. 10.1128/AAC.00638-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Paiva AD, Oliveira MD, de Paula SO, Baracat-Pereira MC, Breukink E, Mantovani HC: Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology. 2012, 158: 2851-2858. 10.1099/mic.0.062190-0.PubMedView ArticleGoogle Scholar
- Russell JB, Mantovani HC: The bacteriocins of ruminal bacteria and their potential as an alternative to antibiotics. J Mol Microbiol Biotechnol. 2002, 4: 347-355.PubMedGoogle Scholar
- de Carvalho AA, Vanetti MC, Mantovani HC: Bovicin HC5 reduces thermal resistance of Alicyclobacillus acidoterrestris in acidic mango pulp. J Appl Microbiol. 2008, 104: 1685-1691. 10.1111/j.1365-2672.2007.03710.x.PubMedView ArticleGoogle Scholar
- Lloyd CM, Gonzalo JA, Coyle AJ, Gutierrez-Ramos JC: Mouse models of allergic airway disease. Adv Immunol. 2001, 77: 263-295.PubMedView ArticleGoogle Scholar
- Saldanha JCS, Gargiulo DL, Silva SS, Carmo-Pinto FH, Andrade MC, Alvarez-Leite JI, Teixeira MM, Cara DC: A model of chronic IgE mediated food allergy in ovalbumin-sensitized mice. Braz J Med Biol Res. 2004, 37: 809-816. 10.1590/S0100-879X2004000600005.PubMedView ArticleGoogle Scholar
- Bischoff SC, Sellge G: Mast cell hyperplasia: Role of cytokines. Int Arch Allergy Immunol. 2002, 127: 118-122. 10.1159/000048181.PubMedView ArticleGoogle Scholar
- Nell MJ, Grote JJ: Effects of bacterial toxins on air-exposed cultured human respiratory sinus epithelium. Ann Otol Rhinol Laryngol. 2003, 112: 461-468.PubMedView ArticleGoogle Scholar
- Zimmermann N, Hershey GK, Foster PS, Rothenberg ME: Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol. 2003, 111: 227-242. 10.1067/mai.2003.139.PubMedView ArticleGoogle Scholar
- Ayabe T, Satchell D, Wilson C, Parks W, Selsted M, Ouellette A: Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol. 2000, 1: 113-118. 10.1038/77783.PubMedView ArticleGoogle Scholar
- Keshav S: Paneth cells: leukocyte-like mediators of innate immunity in the intestine. J Leukoc Biol. 2006, 80: 500-508. 10.1189/jlb.1005556.PubMedView ArticleGoogle Scholar
- Sergent TT, Ribonnet L, Kolosova A, Garsou S, Schaut A, de Saeger S, Peteghem CV, Larodelle Y, Puseemier L, Scheneider Y: Molecular and cellular effects of food contaminants and secondary plant components and their plausible interactions at the intestinal level. Food Chem Toxicol. 2008, 46: 813-841. 10.1016/j.fct.2007.12.006.PubMedView ArticleGoogle Scholar
- Goya I, Villares R, Zaballos A, Gutiérrez J, Kremer L, Gonzalo JA, Varona R, Carramolino L, Serrano A, Pallares P, Criado LM, Kolbeck R, Torres M, Coyle AJ, Gutiérrez-Ramos JC, Martínez C, Márquez G: Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J Immunol. 2003, 170: 2138-2146.PubMedView ArticleGoogle Scholar
- Cardoso CR, Teixeira G, Provinciatto PR, Godoiz DF, Ferreira BR, Milanezi CM, Ferraz DB, Rossi MA, Cunhaz FQ, Silva JS: Modulation of mucosal immunity in a murine model of food-induced intestinal inflammation. Clin Exp Allergy. 2008, 38: 338-349.PubMedGoogle Scholar
- Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, Shimizu K, Tsunoo H: Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem. 1989, 264: 472-478.PubMedGoogle Scholar
- Hsu HC, Hsu CI, Lin RH, Kao CL, Lin JY: Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochem J. 1997, 323: 557-565.PubMedPubMed CentralView ArticleGoogle Scholar
- Ko JL, Hsu CI, Lin RH, Kao CL, Lin JY: A new fungal immunomodulatory protein, FIP-fve isolated from the edible mushroom, Flammulina velutipes and its complete amino acid sequence. Eur J Biochem. 1995, 228: 244-249. 10.1111/j.1432-1033.1995.tb20256.x.PubMedView ArticleGoogle Scholar
- Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ: Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004, 22: 181-215. 10.1146/annurev.immunol.22.012703.104603.PubMedView ArticleGoogle Scholar
- Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, Wang A, Lee K, Doria S, Hamill P: An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol. 2007, 25: 465-472. 10.1038/nbt1288.PubMedView ArticleGoogle Scholar
- Liu YW, Liu JC, Huang CY, Wang CK, Shang HF, Hou WC: Effects of oral administration of yam tuber storage protein, dioscorin, to BALB/c mice for 21-days on immune responses. J Agric Food Chem. 2009, 57: 9274-9279. 10.1021/jf902245k.PubMedView ArticleGoogle Scholar
- Nijnik A, Pistolic J, Wyatt A, Tam S, Hancock REW: Human cathelicidin peptide LL-37 modulates the effects of IFN-γ on APCs. J Immunol. 2009, 183: 5788-5798. 10.4049/jimmunol.0901491.PubMedView ArticleGoogle Scholar
- Davidson DJ, Currie AJ, Reid GS, Bowdish DM, MacDonald KL, Ma RC, Hancock REW, Speert DP: The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol. 2004, 172: 1146-1156.PubMedView ArticleGoogle Scholar
- Akiyama H, Teshima R, Sakushima J, Okunuki H, Goda Y, Sawada J, Toyoda M: Examination of oral sensitization with ovalbumin in Brown Norway rats and three strains of mice. Immunol Lett. 2001, 78: 1-5. 10.1016/S0165-2478(01)00229-2.PubMedView ArticleGoogle Scholar
- Knippels LMJ, Houben GF, Spanhaak S, Penninks AH: An oral sensitization model in Brown Norway rats to screen for potential allergenicity of food proteins. Methods. 1999, 19: 78-82. 10.1006/meth.1999.0830.PubMedView ArticleGoogle Scholar
- Carson FL, Martin JH, Lynn JA: Formalin fixation for electron microscopy: a re-evaluation. Am J Clin Pathol. 1973, 59: 365-373.PubMedGoogle Scholar
- Bancroft JD, Stevens A: Theory and practice of histological techniques. 1996, London: Churchill Livingstone, 4Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.